Mutations of immune system found in breast cancers

November 18, 2013

Mutations in the genes that defend the body against cancer-related viruses and other infections may play a larger role in breast cancer than previously thought, according to a study at the University of Illinois at Chicago.

Bernard Friedenson, associate professor of biochemistry and at UIC, looked at the DNA sequences of breast cancers from 21 different women and found mutations in involved in immunity in every one of them. The mutations were different in each of the breast cancers he analyzed, but all the mutations would have affected some aspect of pathogen recognition and defense, especially against viruses, Friedenson said.

His results are published in the November issue of Functional & Integrative Genomics.

The finding suggests that mutations affecting the immune system play an important role in the development of , contrary to the prevailing notion that mutations in the genes that regulate cell division are primarily responsible. Viruses such as human papilloma virus, which can cause cervical cancer, and Epstein-Barr virus, which can cause certain lymphomas, have also been implicated in breast cancer.

"Almost every human being is infected with one or more of these viruses, but most people never develop symptoms, much less breast cancer," Friedenson said.

Friedenson thinks that cancer-related viruses that are normally harmless can become dangerous if genes involved in immunity are mutated, either through heredity or environmental causes.

He identified gene mutations in breast cancer cells that affect their ability to recognize viruses, including some that would be expected to significantly increase the cells' vulnerability to viruses implicated in breast cancer.

"If we know which genes are damaged in a breast cancer patient's immune system, prevention or even therapy can be tailored by giving vaccines or perhaps antiviral drugs to reduce the chances of recurrence," said Friedenson. "Sequencing the genomes of individual breast cancers now costs about $2,000, and the cost continues to fall. This information could help physicians prescribe more targeted and effective treatments."

Explore further: New risk gene discovery gives hope to early-onset breast cancer sufferers

Related Stories

New risk gene discovery gives hope to early-onset breast cancer sufferers

October 24, 2013
A new breast cancer risk gene has been discovered which explains the early-onset breast cancer in some multiple-case breast cancer families.

BROCA sequencing approach evaluates all 24 genes implicated in breast cancer

October 24, 2013
Since 1994, many thousands of women with breast cancer from families severely affected with the disease have been tested for inherited mutations in BRCA1 and BRCA2. The vast majority of those patients were told that their ...

Breast CA nodal mets more common with certain mutations

July 25, 2013
(HealthDay)—Lymph node metastases are more common in breast cancers with mutations in a cellular signaling pathway associated with growth, according to a study published online July 24 in JAMA Surgery.

No viral cause for breast cancer and brain tumors

October 8, 2013
A major study conducted at the Sahlgrenska Academy has now disproved theories of a viral cause for breast cancer and the brain tumour, glioblastoma. The study, which was based on over seven billion DNA sequences and which ...

Researchers discover enzyme behind breast cancer mutations

February 6, 2013
Researchers at the University of Minnesota have uncovered a human enzyme responsible for causing DNA mutations found in the majority of breast cancers. The discovery of this enzyme – called APOBEC3B – may change the way ...

Two research groups find link between gene mutation and resistance to estrogen cancer therapy

November 4, 2013
(Medical Xpress)—Two teams of researchers, both made up of members from a wide variety of research institutions in the U.S. have independently come up with the same findings: a gene mutation in ESR1 (a gene that encodes ...

Recommended for you

Anti-cancer chemotherapeutic agent inhibits glioblastoma growth and radiation resistance

July 24, 2017
Glioblastoma is a primary brain tumor with dismal survival rates, even after treatment with surgery, chemotherapy and radiation. A small subpopulation of tumor cells—glioma stem cells—is responsible for glioblastoma's ...

New therapeutic approach for difficult-to-treat subtype of ovarian cancer identified

July 24, 2017
A potential new therapeutic strategy for a difficult-to-treat form of ovarian cancer has been discovered by Wistar scientists. The findings were published online in Nature Cell Biology.

Immune cells the missing ingredient in new bladder cancer treatment

July 24, 2017
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.